|
Characteristic, n (%)
|
SUVmax reduction rate
|
P
|
|---|
|
< 60%
|
≥ 60%
|
|---|
|
n=23
|
n=44
|
|---|
|
The interval days between NACRT finished and FDG-PET taken
|
20 (10–46)
|
20 (6–32)
|
0.5705
|
|
Median age (range)
|
65 (47–75)
|
63.5 (41–75)
|
0.5083
|
|
Gender
| | |
0.7546
|
|
Female
|
3 (13.0)
|
7 (15.9)
| |
|
Male
|
20 (87.0)
|
37 (84.1)
| |
|
Tumor location
| | |
0.8080
|
|
Upper
|
5 (21.7)
|
10 (22.7)
| |
|
Middle
|
10 (43.5)
|
22 (50.0)
| |
|
Lower
|
8 (34.8)
|
12 (27.3)
| |
|
Tumor differentiation
| | |
0.7346
|
|
Not poorly
|
21 (91.3)
|
39 (88.6)
| |
|
Poorly
|
2 (8.7)
|
5 (11.4)
| |
|
Depth of invasion (cT)
| | |
0.7813
|
|
T1-2
|
2 (8.7)
|
3 (6.8)
| |
|
T3-4
|
21 (91.3)
|
41 (93.2)
| |
|
Lymph node metastasis (cN)
| | |
0.8980
|
|
N1
|
15 (65.2)
|
28 (63.6)
| |
|
N2-3
|
8 (34.8)
|
16 (36.4)
| |
|
Distant metastasis (cM)
| | |
0.0804
|
|
M0
|
19 (82.6)
|
42 (95.5)
| |
|
M1 ( Lymph node)
|
4 (17.4)
|
2 (4.6)
| |
|
Clinical stage(cStage)
| | |
0.0615
|
|
I
|
2 (8.7)
|
0 (0)
| |
|
II
|
0 (0)
|
3 (6.8)
| |
|
III
|
17 (7.39)
|
38 (86.4)
| |
|
IVA
|
0 (0)
|
1 (2.3)
| |
|
IVB
|
4 (17.4)
|
2 (4.6)
| |
|
Recurrence
| | |
0.0445a
|
|
Presence
|
15 (65.2)
|
17 (38.6)
| |
|
Absence
|
8 (34.8)
|
27 (61.4)
| |
|
Prognosis
| | |
0.1752
|
|
Alive
|
10 (43.5)
|
31 (70.5)
| |
|
Dead with ESCC
|
11 (47.8)
|
10 (22.7)
| |
|
Dead with other diseases
|
2 (8.7)
|
3 (6.8)
| |
- *Statistically significant
